Biokinetic modelling of DTPA decorporation therapy: The CONRAD approach

Radiation Protection Dosimetry

Volumn 134, Issue 1, 2009, Pages 38-48

  Breustedt, Bastian ^a   Blanchardon, E ^b   Berard, P ^c   Fritsch, P ^d   Giussani, A ^e   Lopez, M A ^f   Luciani, A ^g   Nosske, D ^h   Piechowski, J ⁱ   Schimmelpfeng, J ^a   Serandour A L ^d  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d CEA DIF   (France)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f CIEMAT   (Spain)

^g ENEA   (Italy)

^h BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

ⁱ CEA SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PENTETIC ACID; PLUTONIUM;

ARTICLE; CHELATION THERAPY; DOSIMETRY; MOLECULAR MECHANICS; STATISTICAL MODEL; URINARY EXCRETION;

CHELATING AGENTS; HUMANS; KINETICS; MODELS, BIOLOGICAL; PENTETIC ACID; PLUTONIUM; RADIATION INJURIES;

EID: 65549104197     PISSN: 01448420     EISSN: None     Source Type: Journal    
DOI: 10.1093/rpd/ncp058     Document Type: Article

References (36)

1. Lopez, M. A. et al. Coordination of research on internal dosimetry in Europe: The CONRAD project. Radiat. Prot. Dosim. 127(1-4), 311-316 (2007).
2. Nosske, D. et al. The work of the CONRAD Task Group 5.2-research studies on biokinetic models. Radiat. Prot. Dosim. 127(1-4), 93-97 (2007).
3. Kety, S. S. The lead citrate complex ion and its role in the physiology and therapy of lead poisoning. J. Biol. Chem. 14, 181-192 (1942).
4. Volf, V. Treatment of incorporated transuranium elements. IAEA Technical Reports Series No. 184 (Vienna: IAEA) (1978).
5. Ménétrier, F. and Grappin, L. et al. Treatment of accidential intakes of plutonium and americium: Guidance notes. Appl. Radiat. Isot. 62(6), 829 (2005).
6. Wood, R., Sharp, C., Gourmelon, P., Le Guen, B., Stradling, G. N., Taylor, D. M. and Hengé-Napoli, M. H. Decorporation treatment-medical overview. Radiat. Prot. Dosim. 87(1), 51-57 (2000).
7. Roedler, H. D., Nosske, D., Ohlenschlager, L., Schieferdecker, H., Doerfel, H. and Renz, K. Incorporation of 241Am: Effectiveness of late DTPA chelation therapy. Radiat. Prot. Dosim. 26(1-4), 377 (1989).
8. Leggett, R. W., Eckerman, K. F., Khokhryakov, V. F., Suslova, K. G., Krahenbuhl, M. P. and Miller, S. C. Mayak worker study: An improved biokinetic model for reconstructing doses from internally deposited plutonium. Radiat. Res. 164(2), 111-122 (2005).
9. International Commission on Radiation Protection. Radiation dose to patients from radiopharmaceuticals. ICRP Publication 53. Ann. ICRP 18(1-4), 1-377 (1987).
10. Stather, J. W., Smith, H., Bailey, M. R., Birchall, A., Bulman, R. A. and Crawley, F. E. The retention of 14C-DTPA in human volunteers after inhalation or intravenous injection. Health Phys. 22(6), 45-52 (1983).
11. Stevens, W., Bruenger, F. W., Atherton, D. R., Buster, D. S. and Howerton, G. The retention and distribution of 241Am and 65Zn, given as DTPA chelates in rats and of [14C]DTPA in rats and beagles. Radiat. Res. 75, 397-409 (1978).
12. Phan, G., Le Gall, B., Deverre, J. R., Fattal, E. and Benech, H. Predicting plutonium decorporation efficacy after intravenous administration of DTPA formulations: Study of pharmacokinetic-pharmacodynamic relationships in rats. Pharm. Res. 23, 2030-2035 (2006).
13. Hall, R. M., Proda, G. A., Fleming, R. R. and Smith, J. A. A mathematical model for estimation of plutonium in the human body from urine data influenced by DTPA therapy. Health Phys. 34, 419-431 (1978).
14. La Bone, T. R. Evaluation of Intakes of Transuranics influenced by Chelation Therapy. in: Internal Radiation Dosimetry. Raabe, O. G. ed. (Madison: Medical Physics Publishing) (1994).
15. Fritsch, P., Grappin, L., Guillermin, A. M., Fottorino, R., Ruffin, M. and Miele, A. Modeling of bioassay data from a Pu wound treated by repeated DTPA perfusions: Biokinetics and dosimetric approaches. Radiat. Prot. Dosim. 127(1-4), 120-124 (2007).
16. James, A. C., Sasser, L. B., Stuit, D. B., Glover, S. E. and Carbaugh, E. H. USTUR whole body case 0269: Demonstrating effectiveness of I.V. Ca-DTPA for Pu. Radiat. Prot. Dosim. 127(1-4), 449-455 (2007).
17. Food and Drug Administration (FDA). Pentetate calcium trisodium injection: Labeling. Document NDA 27-749 (approved 11 August 2004) (2009). Also available on: http://www.fda.gov/cder/foi/label/2004/ 021749lbl.pdf (accessed on 2 March 2009).
18. Food and Drug Administration (FDA). Pentetate zinc trisodium injection: Labeling. Document NDA 27-751 (approved 11 August 2004) (2009). Also available on: http://www.fda.gov/cder/foi/label/2004/ 021715lbl.pdf (accessed on 2 March 2009).
19. International Commission on Radiological Protection. Human respiratory tract model for radiological protection. ICRP Publication 66. Ann. ICRP 24(1-3) (1994).
20. International Commission on Radiological Protection. Human alimentary tract model for radiological protection. ICRP Publication 100. Ann. ICRP 36(1-2), 25-327 (2006).
21. National Council of Radiation Protection and Measurements. Development of a biokinetic model for radionuclide-contaminated wounds and procedures for their assessment, dosimetry and treatment. NCRP Report No. 156. National Council on Radiation Protection and Measurements. (2007).
22. International Commission on Radiological Protection. Limits on intakes of radionuclides by workers. ICRP Publication 30 (Oxford: Pergamon Press) (1979).
23. Luciani, A. and Polig, E. Verification and modification of the ICRP-67 model for plutonium dose calculation. Health Phys. 78 (3), 303 (2000).
24. Hurtgen, C. et al. IDEAS internal contamination database: A compilation of published internal contamination case. A tool for the internal dosimetry community. Radiat. Prot. Dosim. 125(1-4), 520-522 (2007).
25. Jech, J. J., Andersen, B. V. and Heid, K. R. Interpretation of human urinary excretion of plutonium for cases treated with DTPA. Health Phys. 22, 787 (1972).
26. Jolly, L. Jr, McClearen, H. A., Poda, G. A. and Walke, W. P. Treatment and evaluation of a plutonium-238 nitrate contaminated puncture wound. A two-year case history. Health Phys. 23, 333 (1972).
27. Schofield, G. B., Howells, H. and Ward, F. Assessment and management of a plutonium contaminated wound case. Health Phys. 26, 541 (1974).
28. Grappin, L., Bérard, P., Menetrier, F., Carbone, L., Courtay, C., Castagnet, X., Le Goff, J. P., Neron, M. O. and Piechowski, J. Treatment of actinide exposures: A review of Ca-DTPA injections inside CEA-COGEMA plants. Radiat. Prot. Dosim. 127(1-4), 435-439 (2007).
29. Piechowski, J., Menoux, B., Miele, A., Grappin, L., Guillermin, A.-M., Fottorino, R. and Ruffin, M. Implication of the occupational physician and of the expert in the management and the dosimetry of an accidental contamination (in French). Radioprotection 38(1), 29-50 (2003).
30. Jeanmaire, L. F., Patti, F. and Audren, M. L. Interpretation de résultats après contamination par le plutonium. STI/PUB/84. Assessment of Radioactivity in Man. Proceedings of the Symposium, Heidelberg, Germany, 11-16 May 1964 (1964).
31. Bhattacharyya, M. H., Guilmette, R. A. and Peterson, D. P. Estimation of skeletal plutonium levels based on DTPA-induced radionuclide excretion in feces: Possible application to man. Health Phys. 34 549 (1978).
32. Baxter, D. W. and Sullivan, M. F. Gastrointestinal absorption and retention of plutonium chelates. Health Phys. 22, 785 (1972).
33. Bhattacharyya, M. H. and Peterson, D. P. Action of DTPA on hepatic plutonium. III. Evidence for a direct chelation mechanism for DTPA-induced excretion of monomeric plutonium into rat bile. Radiat. Res. 80(1), 108 (1979).
34. Sérandour, A. L., Grémy, O., Fréchou, M., Renault, D., Poncy, J. L. and Fritsch, P. In vitro and in vivo assessment of plutonium speciation and decorporation in blood and target retention tissues after a systemic contamination followed by an early treatment with DTPA. Radiat. Res. 170(2), 208-215 (2008).
35. Phan, G. and Ramounet-Le-Gall, B. Targeting of diethylene triamine pentaacetic acid encapsulated in liposomes to rat liver: An effective strategy to prevent bone deposition and increase urine elimination of plutonium in rats. Int. J. Radiat. Biol. 80(6), 413-422 (2004).
36. 2 aerosols: Interest in modeling DTPA decorporation. Radioprotection 43(2), 239-253 (2008).